Intensive chemotherapy including cisplatin with or without etoposide for children with soft‐tissue sarcomas

William M. Crist, R. Beverly Raney, Abdel Ragab, Ruth Heyn, Moody Wharam, Bruce Webber, Jean Johnston, Mohan Beltangady

Research output: Contribution to journalArticlepeer-review

Abstract

Forty‐two children, 6 months to 17 years of age with newly diagnosed soft‐tissue sarcomas (gross residual or metastatic), were treated according to either of two pilot protocols that included intensive chemotherapy before irradiation. Vincristine, actinomycin D, cyclophosphamide, and doxorubicin were used in various combinations with cisplatin alone (regimen 35) or with cisplatin plus etoposide (regimen 36) in a 20‐week induction treatment; irradiation (4,000 cGy) was delayed until week 6. Fourteen (82%) of the 17 patients on regimen 35 and 15 (60%) of the 25 on regimen 36 had a complete response. Although severe leukopenia was frequent in both groups (88% and 84% of patients), there were only two fatal infections and no early deaths. Other potentially serious toxicity included a >10% weight loss in 52% of the patients and hypomagnesemia in 74%. An average of 75‐100% of the prescribed drug doses were administered during the induction phase of therapy. We conclude that this intensified treatment is toxic but feasible to deliver. The higher overall response rate compared to that in the preceding Intergroup Rhabdomyosarcoma Study (69% vs 53%) suggests improved therapeutic efficacy that warrants further evaluation of both regimens.

Original languageEnglish (US)
Pages (from-to)51-57
Number of pages7
JournalMedical and Pediatric Oncology
Volume15
Issue number2
DOIs
StatePublished - 1987

Keywords

  • delayed irradiation
  • hypomagnesemia
  • induction treatment
  • rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intensive chemotherapy including cisplatin with or without etoposide for children with soft‐tissue sarcomas'. Together they form a unique fingerprint.

Cite this